SEC Filing Summary: DarioHealth Corp. (DRIO)
Business Context and Reporting Period
This Form 8-K was filed by DarioHealth Corp. on September 12, 2025. The report addresses a regulatory matter regarding the company's continued listing on The Nasdaq Capital Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event.
Material Changes and Events
- Nasdaq Compliance Restored: The company previously received notice on September 16, 2024, of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a failure to maintain the minimum bid price requirement.
- Compliance Period: The Nasdaq Staff determined that for the 10 consecutive business days from August 28, 2025, to September 11, 2025, the closing bid price of the common stock was at or above $1.00 per share.
- Outcome: The company has regained compliance, and the delisting matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks beyond the resolution of the prior listing deficiency. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of DRIO to ensure it remains above the $1.00 minimum bid price threshold.
- Review the company's most recent 10-Q or 10-K for financial health metrics, as this 8-K contains no financial data.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.